Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration
To study retinal pigment epithelium (RPE) tears after off-label intravitreal bevacizumab (Avastin; Genentech, Inc., South San Francisco, CA) injection for neovascular age-related macular degeneration. Eyes with a vascularized pigment epithelial detachment (PED) that developed an RPE tear were compar...
Uloženo v:
| Vydáno v: | Retina (Philadelphia, Pa.) Ročník 27; číslo 5; s. 541 |
|---|---|
| Hlavní autoři: | , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
01.06.2007
|
| Témata: | |
| ISSN: | 0275-004X |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | To study retinal pigment epithelium (RPE) tears after off-label intravitreal bevacizumab (Avastin; Genentech, Inc., South San Francisco, CA) injection for neovascular age-related macular degeneration. Eyes with a vascularized pigment epithelial detachment (PED) that developed an RPE tear were compared with eyes with a vascularized PED but without an RPE tear.
Nine retina specialists across the United States and in Europe participated in this retrospective case series. All eyes that received intravitreal bevacizumab injection for choroidal neovascularization (CNV) over 12 months (October 2005 to September 2006) were included. Eyes without all three confirmed tests (fluorescein angiography, fundus photography, and optical coherence tomography) were excluded from analysis. Statistical analyses were performed on multiple characteristics of eyes with a vascularized PED that did and did not develop an RPE tear.
Among 2,785 intravitreal bevacizumab injections for 1,064 eyes, RPE tears were found in 22 eyes in 22 patients (2.2%). A vascularized PED was present in 21 of 22 eyes that developed an RPE tear (17.1% of PED eyes; 15, 100% occult CNV; 6, predominantly occult CNV). Mean interval from bevacizumab injections to RPE tears was 37.3 days. Mean follow-up time was 124.9 days. Mean subfoveal PED size was larger for eyes with tears than for those without tears (13.97 mm vs 9.9 mm, respectively; P = 0.01; odds ratio, 1.09). There was substantially smaller mean ratio of CNV size to PED size for eyes with tears than for those without tears (27.9% vs 67.6%, respectively; P = 0.005). Mean pre-bevacizumab injection best-corrected Snellen visual acuity was 20/162, and mean post-RPE tear best-corrected visual acuity was 20/160 (P = 0.48).
Large PED size is a predictor for RPE tears, and a small ratio of CNV size to PED size (<50%) is more common in eyes with RPE tears. Vision may be preserved despite RPE tears. |
|---|---|
| AbstractList | To study retinal pigment epithelium (RPE) tears after off-label intravitreal bevacizumab (Avastin; Genentech, Inc., South San Francisco, CA) injection for neovascular age-related macular degeneration. Eyes with a vascularized pigment epithelial detachment (PED) that developed an RPE tear were compared with eyes with a vascularized PED but without an RPE tear.
Nine retina specialists across the United States and in Europe participated in this retrospective case series. All eyes that received intravitreal bevacizumab injection for choroidal neovascularization (CNV) over 12 months (October 2005 to September 2006) were included. Eyes without all three confirmed tests (fluorescein angiography, fundus photography, and optical coherence tomography) were excluded from analysis. Statistical analyses were performed on multiple characteristics of eyes with a vascularized PED that did and did not develop an RPE tear.
Among 2,785 intravitreal bevacizumab injections for 1,064 eyes, RPE tears were found in 22 eyes in 22 patients (2.2%). A vascularized PED was present in 21 of 22 eyes that developed an RPE tear (17.1% of PED eyes; 15, 100% occult CNV; 6, predominantly occult CNV). Mean interval from bevacizumab injections to RPE tears was 37.3 days. Mean follow-up time was 124.9 days. Mean subfoveal PED size was larger for eyes with tears than for those without tears (13.97 mm vs 9.9 mm, respectively; P = 0.01; odds ratio, 1.09). There was substantially smaller mean ratio of CNV size to PED size for eyes with tears than for those without tears (27.9% vs 67.6%, respectively; P = 0.005). Mean pre-bevacizumab injection best-corrected Snellen visual acuity was 20/162, and mean post-RPE tear best-corrected visual acuity was 20/160 (P = 0.48).
Large PED size is a predictor for RPE tears, and a small ratio of CNV size to PED size (<50%) is more common in eyes with RPE tears. Vision may be preserved despite RPE tears. To study retinal pigment epithelium (RPE) tears after off-label intravitreal bevacizumab (Avastin; Genentech, Inc., South San Francisco, CA) injection for neovascular age-related macular degeneration. Eyes with a vascularized pigment epithelial detachment (PED) that developed an RPE tear were compared with eyes with a vascularized PED but without an RPE tear.PURPOSETo study retinal pigment epithelium (RPE) tears after off-label intravitreal bevacizumab (Avastin; Genentech, Inc., South San Francisco, CA) injection for neovascular age-related macular degeneration. Eyes with a vascularized pigment epithelial detachment (PED) that developed an RPE tear were compared with eyes with a vascularized PED but without an RPE tear.Nine retina specialists across the United States and in Europe participated in this retrospective case series. All eyes that received intravitreal bevacizumab injection for choroidal neovascularization (CNV) over 12 months (October 2005 to September 2006) were included. Eyes without all three confirmed tests (fluorescein angiography, fundus photography, and optical coherence tomography) were excluded from analysis. Statistical analyses were performed on multiple characteristics of eyes with a vascularized PED that did and did not develop an RPE tear.METHODSNine retina specialists across the United States and in Europe participated in this retrospective case series. All eyes that received intravitreal bevacizumab injection for choroidal neovascularization (CNV) over 12 months (October 2005 to September 2006) were included. Eyes without all three confirmed tests (fluorescein angiography, fundus photography, and optical coherence tomography) were excluded from analysis. Statistical analyses were performed on multiple characteristics of eyes with a vascularized PED that did and did not develop an RPE tear.Among 2,785 intravitreal bevacizumab injections for 1,064 eyes, RPE tears were found in 22 eyes in 22 patients (2.2%). A vascularized PED was present in 21 of 22 eyes that developed an RPE tear (17.1% of PED eyes; 15, 100% occult CNV; 6, predominantly occult CNV). Mean interval from bevacizumab injections to RPE tears was 37.3 days. Mean follow-up time was 124.9 days. Mean subfoveal PED size was larger for eyes with tears than for those without tears (13.97 mm vs 9.9 mm, respectively; P = 0.01; odds ratio, 1.09). There was substantially smaller mean ratio of CNV size to PED size for eyes with tears than for those without tears (27.9% vs 67.6%, respectively; P = 0.005). Mean pre-bevacizumab injection best-corrected Snellen visual acuity was 20/162, and mean post-RPE tear best-corrected visual acuity was 20/160 (P = 0.48).RESULTSAmong 2,785 intravitreal bevacizumab injections for 1,064 eyes, RPE tears were found in 22 eyes in 22 patients (2.2%). A vascularized PED was present in 21 of 22 eyes that developed an RPE tear (17.1% of PED eyes; 15, 100% occult CNV; 6, predominantly occult CNV). Mean interval from bevacizumab injections to RPE tears was 37.3 days. Mean follow-up time was 124.9 days. Mean subfoveal PED size was larger for eyes with tears than for those without tears (13.97 mm vs 9.9 mm, respectively; P = 0.01; odds ratio, 1.09). There was substantially smaller mean ratio of CNV size to PED size for eyes with tears than for those without tears (27.9% vs 67.6%, respectively; P = 0.005). Mean pre-bevacizumab injection best-corrected Snellen visual acuity was 20/162, and mean post-RPE tear best-corrected visual acuity was 20/160 (P = 0.48).Large PED size is a predictor for RPE tears, and a small ratio of CNV size to PED size (<50%) is more common in eyes with RPE tears. Vision may be preserved despite RPE tears.CONCLUSIONLarge PED size is a predictor for RPE tears, and a small ratio of CNV size to PED size (<50%) is more common in eyes with RPE tears. Vision may be preserved despite RPE tears. |
| Author | Chan, Clement K Kokame, Gregg T Gross, Jeffrey G Kaiser, Peter K Abraham, Prema Lin, Steven G Nuthi, Asha S D Rauser, Michael E Meyer, Carsten H |
| Author_xml | – sequence: 1 givenname: Clement K surname: Chan fullname: Chan, Clement K email: Pschan@aol.com organization: Southern California Desert Retina Consultants, Palm Springs, CA 92263, USA. Pschan@aol.com – sequence: 2 givenname: Carsten H surname: Meyer fullname: Meyer, Carsten H – sequence: 3 givenname: Jeffrey G surname: Gross fullname: Gross, Jeffrey G – sequence: 4 givenname: Prema surname: Abraham fullname: Abraham, Prema – sequence: 5 givenname: Asha S D surname: Nuthi fullname: Nuthi, Asha S D – sequence: 6 givenname: Gregg T surname: Kokame fullname: Kokame, Gregg T – sequence: 7 givenname: Steven G surname: Lin fullname: Lin, Steven G – sequence: 8 givenname: Michael E surname: Rauser fullname: Rauser, Michael E – sequence: 9 givenname: Peter K surname: Kaiser fullname: Kaiser, Peter K |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/17558314$$D View this record in MEDLINE/PubMed |
| BookMark | eNo1kM1LxDAQxXNYcT_0PxDJyVvXJG3S9CiLX7AgiIK3Mkmna5Y2rWm64P71VlxPA7_33jDzlmTmO4-EXHG25qzIbx3gmhnGU0y5ZtYKxcWMLJjIZcJY9jEny2HYM8al1vKczHkupU55tiDHV4zOQ0N7t2vRR4q9i5_YuAlFhDBQqCMG6nwMcHAx4CQYPIB1x7EFMwl7tNF1ntZdoB67Awx2bCBQ2GESsIGIFW3hj1W4Q48BfgMX5KyGZsDL01yR94f7t81Tsn15fN7cbRMrtIqJtKIudA15BgoF8lpOL4pMCm5RKVPowqRcZpmuc4OWqUpbw6q0VikrUAkQK3Lzt7cP3deIQyxbN1hsGpiuHYcyZ4plUuaT8fpkHE2LVdkH10L4Lv_bEj-wC3FK |
| CitedBy_id | crossref_primary_10_1111_ceo_12374 crossref_primary_10_1111_aos_13359 crossref_primary_10_1038_eye_2014_233 crossref_primary_10_1097_IAE_0b013e31817d5d03 crossref_primary_10_1097_IAE_0b013e3181d87e97 crossref_primary_10_1038_eye_2008_401 crossref_primary_10_1177_24741264211028441 crossref_primary_10_1111_j_1755_3768_2009_01547_x crossref_primary_10_1038_eye_2012_90 crossref_primary_10_1016_j_jcjo_2013_01_023 crossref_primary_10_1186_s40942_021_00299_4 crossref_primary_10_3390_jcm12175496 crossref_primary_10_1016_j_ophtha_2011_05_026 crossref_primary_10_1080_08820530903124276 crossref_primary_10_3928_23258160_20130909_07 crossref_primary_10_1007_s00347_008_1839_3 crossref_primary_10_1007_s00347_013_2883_1 crossref_primary_10_3390_jcm12155145 crossref_primary_10_1016_j_ajo_2022_03_023 crossref_primary_10_1111_j_1442_9071_2009_02017_x crossref_primary_10_1097_IAE_0000000000002389 crossref_primary_10_1007_s00717_009_0346_5 crossref_primary_10_1111_j_1442_9071_2008_01710_x crossref_primary_10_1111_j_1442_9071_2009_02043_x crossref_primary_10_1007_s00347_017_0586_8 crossref_primary_10_1097_IAE_0000000000004316 crossref_primary_10_1097_IAE_0000000000004315 crossref_primary_10_5301_EJO_2010_2285 crossref_primary_10_1038_eye_2011_146 crossref_primary_10_1186_s12886_025_03848_9 crossref_primary_10_1097_IAE_0000000000003083 crossref_primary_10_1007_s00347_013_2954_3 crossref_primary_10_1097_IAE_0000000000002311 crossref_primary_10_1038_eye_2008_145 crossref_primary_10_1097_IAE_0000000000001342 crossref_primary_10_1097_IAE_0000000000002029 crossref_primary_10_1159_000439445 crossref_primary_10_2165_11589330_000000000_00000 crossref_primary_10_1097_IAE_0b013e318240a516 crossref_primary_10_1097_IAE_0b013e318263d139 crossref_primary_10_1111_aos_13052 crossref_primary_10_1016_j_survophthal_2017_03_004 crossref_primary_10_1016_j_optm_2010_09_010 crossref_primary_10_3109_15569527_2013_844702 crossref_primary_10_1111_aos_12234 crossref_primary_10_1007_s40123_020_00291_5 crossref_primary_10_1111_j_1755_3768_2012_02426_x crossref_primary_10_1167_iovs_18_26478 crossref_primary_10_1097_IAE_0000000000003922 crossref_primary_10_1097_IAE_0000000000002713 crossref_primary_10_1097_IAE_0b013e31817e100f crossref_primary_10_1097_IAE_0b013e31826d8ff4 crossref_primary_10_1007_s00347_008_1701_7 crossref_primary_10_1097_IAE_0b013e3182755793 crossref_primary_10_1007_s00417_009_1067_9 crossref_primary_10_1007_s40135_014_0057_1 crossref_primary_10_1111_aos_12112 crossref_primary_10_1177_11206721241238391 crossref_primary_10_1097_IAE_0b013e3181babda5 crossref_primary_10_1038_sj_eye_6703098 crossref_primary_10_1007_s10792_008_9243_1 crossref_primary_10_3928_23258160_20190905_16 crossref_primary_10_1007_s00417_011_1734_5 crossref_primary_10_1097_IAE_0b013e31829f73eb crossref_primary_10_1111_j_1755_3768_2008_01312_x crossref_primary_10_1016_j_ajoc_2020_100916 crossref_primary_10_1097_IAE_0000000000001876 crossref_primary_10_1097_IAE_0000000000000823 crossref_primary_10_1007_s00417_013_2549_3 crossref_primary_10_1016_j_ophtha_2008_08_012 crossref_primary_10_1007_s00347_014_3098_9 crossref_primary_10_5301_ejo_5000388 crossref_primary_10_1517_17425255_2013_796928 crossref_primary_10_1016_j_jcro_2014_09_006 crossref_primary_10_1097_ICB_0b013e31817f2e1b crossref_primary_10_1097_IAE_0b013e318207d1a3 crossref_primary_10_1097_ICB_0000000000000184 crossref_primary_10_1016_j_oret_2022_01_019 crossref_primary_10_1097_IAE_0000000000003426 crossref_primary_10_1177_1120672117747034 crossref_primary_10_1007_s00347_008_1702_6 crossref_primary_10_3109_08820538_2011_571055 crossref_primary_10_1007_s00417_015_2978_2 crossref_primary_10_1016_j_survophthal_2020_05_003 crossref_primary_10_1097_IAE_0b013e3182993f66 crossref_primary_10_1097_IAE_0b013e3182278ab4 crossref_primary_10_1097_IAE_0b013e31828992f5 crossref_primary_10_1038_eye_2011_66 crossref_primary_10_1097_IAE_0b013e318195cad5 crossref_primary_10_3928_15428877_20091030_06 crossref_primary_10_1097_IAE_0b013e318297a061 crossref_primary_10_1155_2021_9994098 crossref_primary_10_1517_14712598_2012_660523 crossref_primary_10_1159_000514991 crossref_primary_10_1097_IAE_0000000000000056 crossref_primary_10_1097_IAE_0b013e31820a675a crossref_primary_10_1016_j_survophthal_2010_08_006 crossref_primary_10_2165_00002512_200926040_00002 crossref_primary_10_1038_eye_2011_278 crossref_primary_10_1097_IAE_0b013e3182947811 crossref_primary_10_1111_aos_12683 crossref_primary_10_1016_j_ophtha_2012_01_050 crossref_primary_10_3341_kjo_2016_30_4_265 crossref_primary_10_1007_s00417_017_3762_2 crossref_primary_10_1097_IAE_0b013e3181cdf366 crossref_primary_10_1007_s10384_008_0510_5 crossref_primary_10_1038_eye_2009_271 crossref_primary_10_1007_s00347_007_1655_1 crossref_primary_10_1016_j_ophtha_2014_08_020 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1097/iae.0b013e3180cc2612 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| ExternalDocumentID | 17558314 |
| Genre | Multicenter Study Journal Article Case Reports |
| GroupedDBID | --- .-D .GJ .Z2 01R 0R~ 123 1J1 2V- 40H 53G 5VS 71W 77Y 7O~ AAAAV AAAXR AAGIX AAHPQ AAIQE AAMOA AAMTA AAQKA AAQQT AARTV AASCR AASOK AAXQO AAYEP ABASU ABBUW ABDIG ABJNI ABOCM ABPXF ABVCZ ABXRP ABXVJ ABZAD ABZZY ACCJW ACDDN ACEWG ACGFS ACILI ACLDA ACWDW ACWRI ACXJB ACXNZ ACZKN ADFPA ADGGA ADHPY ADNKB AE3 AE6 AEETU AFBFQ AFDTB AFFNX AFMFY AFUWQ AGINI AHOMT AHPAA AHQNM AHVBC AIJEX AINUH AJCLO AJIOK AJNWD AJNYG AJZMW AKCTQ AKULP ALKUP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW AOQMC BOYCO BQLVK BS7 C45 CGR CS3 CUY CVF DIWNM DUNZO E.X EBS ECM EEVPB EIF EJD ERAAH EX3 F2K F2L F2M F2N F5P FCALG FL- FW0 GNXGY GQDEL H0~ HLJTE HZ~ IKREB IKYAY IN~ IPNFZ JK3 JK8 K8S KD2 KMI L-C N9A NPM N~7 N~B N~M O9- OCUKA ODA OL1 OLG OLH OLU OLV OLY OLZ OPUJH ORVUJ OUVQU OVD OVDNE OVIDH OVLEI OXXIT P-K R58 RIG RLZ S4R S4S ST3 TEORI TSPGW V2I W3M WOQ WOW X3V X3W YFH ZFV ZGI ZZMQN 7X8 ADKSD |
| ID | FETCH-LOGICAL-c286t-5c2f98fa74a6e2e1f518024521ce66b989b315448f7bec06d8cb0d3f6309e62a2 |
| IEDL.DBID | 7X8 |
| ISSN | 0275-004X |
| IngestDate | Thu Oct 02 06:38:05 EDT 2025 Mon Jul 21 05:38:18 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c286t-5c2f98fa74a6e2e1f518024521ce66b989b315448f7bec06d8cb0d3f6309e62a2 |
| Notes | ObjectType-Case Study-2 SourceType-Scholarly Journals-1 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3 |
| PMID | 17558314 |
| PQID | 70604557 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_70604557 pubmed_primary_17558314 |
| PublicationCentury | 2000 |
| PublicationDate | 2007-Jun 20070601 |
| PublicationDateYYYYMMDD | 2007-06-01 |
| PublicationDate_xml | – month: 06 year: 2007 text: 2007-Jun |
| PublicationDecade | 2000 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Retina (Philadelphia, Pa.) |
| PublicationTitleAlternate | Retina |
| PublicationYear | 2007 |
| SSID | ssj0015885 |
| Score | 2.246462 |
| Snippet | To study retinal pigment epithelium (RPE) tears after off-label intravitreal bevacizumab (Avastin; Genentech, Inc., South San Francisco, CA) injection for... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 541 |
| SubjectTerms | Aged Aged, 80 and over Angiogenesis Inhibitors - administration & dosage Angiogenesis Inhibitors - adverse effects Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal, Humanized Bevacizumab Choroidal Neovascularization - drug therapy Female Fluorescein Angiography Humans Injections Macular Degeneration - drug therapy Male Pigment Epithelium of Eye - drug effects Pigment Epithelium of Eye - pathology Retinal Detachment - chemically induced Retinal Detachment - diagnosis Retinal Perforations - chemically induced Retinal Perforations - diagnosis Retrospective Studies Tomography, Optical Coherence Vascular Endothelial Growth Factor A - antagonists & inhibitors Vitreous Body |
| Title | Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/17558314 https://www.proquest.com/docview/70604557 |
| Volume | 27 |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV05T8MwFLa4hFi478sDq9Ukji8JCSEEgoEKIZC6VY5jo6A2LRQ68Ot5z23ohBhYMiRxlDifn793E3ImBPcmGM5g68tYblPBjFMJ8ylXngeblkWIzSZUu607HfMwR86bXBgMq2xkYhTU5cChjbwVq7wIoS6Gbwx7RqFvddpAY54sciAyuCxVZ-ZDEDo25ES_HAModJrEOaNad5fXMwtg4hzW0fqdYsat5mbtfy-5TlanFJNeTjCxQeZ8vUmW76dO9C3y9YhpznDHsHpB2yD1Q0zM6AESKUb3jmhsHE4rtPuOKwxF79HCj62rvj77toALrzGAq6bAeGntf8JZKQgnFrNjfEn7dnKu9C-xtDUO2CbPN9dPV7ds2oKBuUzLDyZcFowOVuVW-synQWDFuBz2fOelLIw2Bcd6PjooAEMiS-2KpORB8sR4mdlshyzUg9rvEZqm8JTMgsYNHM0CDGSQyjhQL0Fp8jrfJ6fNnHYB4ui3sPAFn6NuM6v7ZHfyW7rDSSWOLnAfoXmaH_w59pCsNJF-SXpEFgMsbn9Mltz4oxq9n0TkwLH9cP8N2JjPww |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Retinal+pigment+epithelial+tears+after+intravitreal+bevacizumab+injection+for+neovascular+age-related+macular+degeneration&rft.jtitle=Retina+%28Philadelphia%2C+Pa.%29&rft.au=Chan%2C+Clement+K&rft.au=Meyer%2C+Carsten+H&rft.au=Gross%2C+Jeffrey+G&rft.au=Abraham%2C+Prema&rft.date=2007-06-01&rft.issn=0275-004X&rft.volume=27&rft.issue=5&rft.spage=541&rft_id=info:doi/10.1097%2FIAE.0b013e3180cc2612&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0275-004X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0275-004X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0275-004X&client=summon |